[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650722":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":24,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":24,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":24,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Charm Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CHM-029 Dose Escalation","EXPERIMENTAL","Participants will receive CHM-029 orally. Dose levels will be escalated based on dose limiting toxicities (DLTs) as evaluated by the Safety Review Committee (SRC).",[13],"Drug: CHM-029",{"label":15,"type":10,"description":16,"interventionNames":17},"CHM-029 Backfill","Participants will receive CHM-029 orally at a dose level already evaluated by the Safety Review Committee (SRC).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","CHM-029","CHM-029 is administered orally.",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Charm Study Contact","CONTACT","312-682-0586","clinicaltrials@charmtx.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"START Midwest","RECRUITING","Grand Rapids","Michigan","49546","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-85.66809,42.96336,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":24,"phoneExt":24,"email":24},"Andrew Sochacki, MD",{"type":50,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100650722","phase-1-a-study-of-chm-029-in-participants-with-npm1-mutated-kmt2a-or-nup98-rearranged-aml-100650722",false,"NCT07751991","A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML","A Phase 1\u002F2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements","Inclusion Criteria:\n\n* 18 years old and above\n* Relapsed or refractory (R\u002FR) acute myeloid leukemia (AML) and has had treatment with any available standard therapies\n* Positive for NPM1 mutation, or KMT2A or NUP98 rearrangements\n\nExclusion Criteria:\n\n* White blood cell (WBC) count higher than 25,000 u\u002FL that cannot be maintained below threshold with hydroxyurea treatment\n* Extramedullary only AML\n* Has current complications related to hematopoietic stem cell transplant (HSCT)\n* Other cancers that require treatment\n* Active Hepatitis or HIV infection\n* Moderate hepatic or renal impairment\n* Acute promyelocytic leukemia\n* Baseline prolongation of QT\u002FQTc interval (≥ 470 ms) or additional risk factors for Torsades de Pointes (TdP)\n* Congestive heart failure NYHA Class 3 or 4\n* Central nervous system involvement refractory to intrathecal chemotherapy and\u002For standard cranial-spinal radiation","ALL","18 Years",{"count":61,"type":62},40,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The main questions the study aims to answer are:\n\n* What is an appropriate dose of CHM-029?\n* What side effects may occur with CHM-029?\n* How does the body process CHM-029?\n\nResearchers will evaluate increasing dose levels of CHM-029 to better understand its safety and how the body responds to treatment.\n\nParticipants will visit the study clinic regularly for safety assessments, blood tests, electrocardiograms (ECGs), and bone marrow evaluations to monitor their health and response to treatment.",[68],"AML (Acute Myeloid Leukemia)",[21,70,71,72,73,74,75,76],"AML","Menin","leukemia","NPM1","KMT2A","NUP98","Charm","2026-08-03",{"date":79,"type":80},"2026-08-07","ACTUAL",{"date":82,"type":62},"2026-08",{"date":84,"type":62},"2029-03",{"name":5,"class":6},1]